Management of Cognitive and Negative Symptoms in Schizophrenia

Overview

Journal Ment Health Clin

Specialty Psychiatry

Date 2022 Nov 21

PMID 36405508

Authors

Megan Maroney

Affiliations

Soon will be listed here.

Abstract

Currently available antipsychotics provide only modest benefit in managing the cognitive and negative symptoms of schizophrenia even though these symptoms are often the most impairing in patients' daily lives. Certain antipsychotics may have slight benefits over others, and several nonpharmacologic and pharmacologic adjunctive treatments have been evaluated in recent clinical trials. Recently published meta-analyses and clinical studies of such treatments are reviewed. Potential strategies to manage cognitive and negative symptoms, including deprescribing of medications that may exacerbate these symptoms, are described using theoretical case examples.

Citing Articles

The awareness, characterization, and burden of Cognitive Impairment Associated with Schizophrenia (CIAS) in clinical practice: Results from a nationwide survey in Italy.

Vita A, Barlati S, Cavallaro R, Cipelli R, Corrivetti G, Delmonte D Schizophr Res Cogn. 2025; 40:100352.

PMID: 40046087 PMC: 11880602. DOI: 10.1016/j.scog.2025.100352.

Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives.

Vita A, Nibbio G, Barlati S Schizophr Bull Open. 2024; 5(1):sgae013.

PMID: 39144119 PMC: 11207676. DOI: 10.1093/schizbullopen/sgae013.

Clinical decision-making before discharge in hospitalized persons with schizophrenia: a Spanish Delphi expert consensus.

Montes J, Aguera-Ortiz L, Mane A, Martinez-Raga J, Gutierrez-Rojas L Front Psychiatry. 2024; 15:1412637.

PMID: 38915849 PMC: 11194714. DOI: 10.3389/fpsyt.2024.1412637.

Editorial: Innovative treatments for neuro-psychiatric diseases.

Gozzo L, Spina E, Drago F Front Neurosci. 2023; 17:1247681.

PMID: 37483343 PMC: 10362339. DOI: 10.3389/fnins.2023.1247681.

References

Zheng W, Cai D, Zhang Q, He J, Zhong L, Sim K . Adjunctive ondansetron for schizophrenia: A systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2019; 113:27-33. DOI: 10.1016/j.jpsychires.2019.02.024. View

Veselinovic T, Scharpenberg M, Heinze M, Cordes J, Muhlbauer B, Juckel G . Disparate effects of first and second generation antipsychotics on cognition in schizophrenia - Findings from the randomized NeSSy trial. Eur Neuropsychopharmacol. 2019; 29(6):720-739. DOI: 10.1016/j.euroneuro.2019.03.014. View

Desmarais J, Beauclair L, Annable L, Belanger M, Kolivakis T, Margolese H . Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Ther Adv Psychopharmacol. 2014; 4(6):257-67. PMC: 4257986. DOI: 10.1177/2045125314553611. View

Vita A, Barlati S, Ceraso A, Nibbio G, Ariu C, Deste G . Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Psychiatry. 2021; 78(8):848-858. PMC: 8058696. DOI: 10.1001/jamapsychiatry.2021.0620. View

Huerta-Ramos E, Labad J, Cobo J, Nunez C, Creus M, Garcia-Pares G . Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial. Eur Arch Psychiatry Clin Neurosci. 2019; 270(6):729-737. DOI: 10.1007/s00406-019-01079-w. View

Turner D, McGlanaghy E, Cuijpers P, van der Gaag M, Karyotaki E, MacBeth A . A Meta-Analysis of Social Skills Training and Related Interventions for Psychosis. Schizophr Bull. 2017; 44(3):475-491. PMC: 5890475. DOI: 10.1093/schbul/sbx146. View

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N . Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019; 394(10202):939-951. PMC: 6891890. DOI: 10.1016/S0140-6736(19)31135-3. View

Weickert T, Weinberg D, Lenroot R, Catts S, Wells R, Vercammen A . Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry. 2015; 20(6):685-94. PMC: 4444978. DOI: 10.1038/mp.2015.11. View

Carbon M, Correll C . Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014; 19 Suppl 1:38-52. DOI: 10.1017/S1092852914000601. View

10.

Keefe R, Bilder R, Davis S, Harvey P, Palmer B, Gold J . Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007; 64(6):633-47. DOI: 10.1001/archpsyc.64.6.633. View

11.

Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B . Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014; 153(1-3):169-76. DOI: 10.1016/j.schres.2014.01.011. View

12.

Correll C, Schooler N . Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020; 16:519-534. PMC: 7041437. DOI: 10.2147/NDT.S225643. View

13.

Kishi T, Ikuta T, Oya K, Matsunaga S, Matsuda Y, Iwata N . Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol. 2018; 21(8):748-757. PMC: 6070030. DOI: 10.1093/ijnp/pyy045. View

14.

Galling B, Vernon J, Pagsberg A, Wadhwa A, Grudnikoff E, Seidman A . Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand. 2018; 137(3):187-205. DOI: 10.1111/acps.12854. View

15.

Allott K, van-der-El K, Bryce S, Parrish E, McGurk S, Hetrick S . Compensatory Interventions for Cognitive Impairments in Psychosis: A Systematic Review and Meta-Analysis. Schizophr Bull. 2020; 46(4):869-883. PMC: 7345816. DOI: 10.1093/schbul/sbz134. View

16.

Dal Santo F, Jarratt-Barnham I, Gonzalez-Blanco L, Garcia-Portilla M, Bobes J, Fernandez-Egea E . Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: A mediation model. Eur Neuropsychopharmacol. 2020; 33:158-163. DOI: 10.1016/j.euroneuro.2020.01.016. View

17.

Lutgens D, Gariepy G, Malla A . Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis. Br J Psychiatry. 2017; 210(5):324-332. DOI: 10.1192/bjp.bp.116.197103. View

18.

Desamericq G, Schurhoff F, Meary A, Szoke A, Macquin-Mavier I, Bachoud-Levi A . Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol. 2013; 70(2):127-34. DOI: 10.1007/s00228-013-1600-y. View

19.

Santos B, Gonzalez-Fraile E, Zabala A, Guillen V, Rueda J, Ballesteros J . Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia. J Psychopharmacol. 2018; 32(11):1155-1166. DOI: 10.1177/0269881118805496. View

20.

Martinez A, Brea J, Rico S, Teresa de Los Frailes M, Loza M . Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments. Int J Mol Sci. 2021; 22(18). PMC: 8468549. DOI: 10.3390/ijms22189905. View